Advanced Search Results For "Pancreatic Neoplasms genetics"
Your filters
Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Publication Type: Academic Journal
Source(s): Annals of surgical oncology [Ann Surg Oncol] 2023 Mar; Vol. 30 (3), pp. 1312-1326. Date of Electronic Publication: 2022 Nov 05.
Abstract: Background: The National Comprehensive Cancer Network recommends genetic testing in patients with potentially hereditary breast, ovarian, pancreatic, and prostate cancers (HBOPP). Knowledge of genetic mutations impacts decisions about screening and tre...
Investigation of -PRKACA/-PRKACB fusion genes in oncocytic tumors of the pancreatobiliary and other systems.
Publication Type: Academic Journal
Source(s): Virchows Archiv : an international journal of pathology [Virchows Arch] 2022 Dec; Vol. 481 (6), pp. 865-876. Date of Electronic Publication: 2022 Sep 24.
Abstract: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreatobiliary system are tumors comprising oncocytic cells, in which three types of fusion genes involving -PRKACA/-PRKACB were recently identified. IOPNs infrequently combine with other histo...
ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis.
Publication Type: Academic Journal
Source(s): British journal of cancer [Br J Cancer] 2022 Nov; Vol. 127 (8), pp. 1461-1472. Date of Electronic Publication: 2022 Aug 19.
Abstract: Background: Desmoplastic stroma, a feature of pancreatic ductal adenocarcinoma (PDAC), contains abundant activated pancreatic stellate cells (PSCs). How PSCs promote PDAC progression remains incompletely understood.Methods: Effect of epithelium-specifi...
Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.
Publication Type: Academic Journal
Source(s): Journal of clinical gastroenterology [J Clin Gastroenterol] 2023 Mar 01; Vol. 57 (3), pp. 317-323. Date of Electronic Publication: 2023 Mar 01.
Abstract: Background: The natural history of branch-duct intraductal papillary neoplasm (BD-IPMN) in BRCA1/2 patients is unknown. Our goal was to estimate the incidence and prevalence of BD-IPMN and other pancreatic lesions in BRCA1/2 patients and compare it to ...
Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
Publication Type: Academic Journal
Source(s): Familial cancer [Fam Cancer] 2023 Jan; Vol. 22 (1), pp. 91-97. Date of Electronic Publication: 2022 Jun 17.
Abstract: Germline genetic testing is recommended for all patients with pancreatic cancer (PC) but uptake rates are low. We implemented a mainstreaming program in oncology clinics to increase testing for PC patients. Genetic counselors trained oncology providers...
Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1.
Publication Type: Academic Journal
Source(s): Oncogene [Oncogene] 2023 Feb; Vol. 42 (7), pp. 491-500. Date of Electronic Publication: 2022 Nov 10.
Abstract: Pancreatic stellate cells (PSCs) are key to the treatment-refractory desmoplastic phenotype of pancreatic ductal adenocarcinoma (PDAC) and have received considerable attention as a stromal target for cancer therapy. This approach demands detailed under...
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
Publication Type: Academic Journal
Source(s): Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2023 Feb 01; Vol. 31 (2), pp. 503-516. Date of Electronic Publication: 2022 Nov 15.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with poor prognosis. Gemcitabine-based chemotherapy has become one of the main modalities of its management. However, gemcitabine resistance frequently occurs, leading to failure of PDAC ther...
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Publication Type: Academic Journal
Source(s): Clinical chemistry [Clin Chem] 2023 Mar 01; Vol. 69 (3), pp. 295-307.
Abstract: Background: KRAS circulating tumor DNA (ctDNA) has shown biomarker potential for pancreatic ductal adenocarcinoma (PDAC) but has not been applied in clinical routine yet. We aim to improve clinical applicability of ctDNA detection in PDAC and to study ...
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer.
Publication Type: Academic Journal
Source(s): Molecular cancer [Mol Cancer] 2023 Jan 12; Vol. 22 (1), pp. 8. Date of Electronic Publication: 2023 Jan 12.
Abstract: Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections at the initial stage, which makes the majority of the treatment options largely unsuccessful and leads t...
Keratin19 promotes pancreatic cancer progression and poor prognosis via activating the Hedgehog pathway.
Publication Type: Academic Journal
Source(s): International journal of oncology [Int J Oncol] 2023 Mar; Vol. 62 (3). Date of Electronic Publication: 2023 Feb 24.
Abstract: Pancreatic cancer is a serious threat to human health, with strong invasiveness, rapid progression and poor prognosis. Tumors expressing keratin 19 (K19) have stronger invasiveness and a worse prognosis. However, the role and mechanism of K19 in pancre...